Digital Engage Johnson City has announced an expansion of its comprehensive digital marketing services to better serve businesses across all industries in the Johnson City, Tennessee area. The marketing agency, which has been operating since 2011, is responding to increased demand for integrated online marketing solutions that deliver measurable results for local businesses.
The expanded service offerings encompass web design, search engine optimization, social media management, paid search advertising, and reputation management. The company specializes in creating customized marketing strategies for diverse sectors, including medical practices, legal firms, restaurants, retail establishments, and home service providers throughout the Johnson City region.
“Businesses in Johnson City are recognizing that effective digital marketing services require more than just having a website,” said a Digital Engage spokesperson. “They need comprehensive strategies that integrate multiple channels and platforms to reach their target audiences effectively. Our expanded services address this growing need by providing everything from website hosting and support to local map SEO and social media management under one roof.”
The company’s approach focuses on developing bespoke marketing solutions tailored to each client’s specific industry requirements and business goals. Digital Engage works with various website platforms, including WordPress, Shopify, Squarespace, and WooCommerce, allowing businesses to maintain their preferred systems while enhancing their online presence.
Recent client feedback has highlighted the agency’s ability to deliver consistent results across different industries. The company maintains a 4.8-star rating based on numerous client reviews, with businesses particularly noting the agency’s responsiveness and technical expertise in digital marketing implementation.
The expansion comes at a time when Tennessee businesses are increasingly prioritizing their online presence. Digital Engage’s services now include advanced local map SEO techniques designed to help businesses improve their visibility in location-based searches, a critical factor for attracting customers in competitive local markets.
“Companies that want to learn more about digital marketing often discover that success requires ongoing optimization and adaptation,” noted another Digital Engage representative. “Our expanded services provide businesses with the tools and expertise they need to maintain a competitive edge in their respective markets while focusing on their core operations.”
The agency’s service portfolio includes search engine optimization, pay-per-click management through Google and Bing platforms, Facebook and Instagram advertising, email marketing campaigns, and comprehensive reputation management services. Additionally, Digital Engage provides technical support including website hosting with a 97 percent uptime guarantee, domain registration, and ongoing web support services.
Digital Engage Johnson City serves businesses throughout the Johnson City area and maintains additional operations in Nashville and Knoxville. The company employs a team of digital marketing specialists who work directly with clients to develop and implement customized marketing strategies. Since its founding, the agency has built a diverse portfolio serving clients in healthcare, legal services, hospitality, retail, and numerous other sectors, establishing itself as a comprehensive resource for businesses seeking to enhance their digital presence and reach new customers through strategic online marketing initiatives.
###
For more information about Digital Engage Johnson City, contact the company here:
Digital Engage Johnson City Digital Engage 423-397-2467 help@digitalengage.net 311 Lamont Street, Johnson City, TN 37604
Markhoff & Mittman, P.C. announced this month an expansion of its workers’ compensation legal practice to address a sustained increase in workplace injury claims across multiple industries in the New York metropolitan area. The development reflects a strategic adjustment by the firm to allocate additional legal resources toward workers’ compensation matters involving construction, transportation, healthcare, and municipal employment. The expansion is intended to improve case capacity and procedural efficiency while maintaining compliance with state workers’ compensation regulations.
“Workplace injury claims involve strict statutory timelines and administrative procedures that differ from other areas of civil litigation,” said Brian Mittman, attorney at Markhoff & Mittman, P.C. “The firm has adjusted internal staffing and case management processes to ensure these matters are handled with the level of attention required under the workers’ compensation system.”
Founded in 1979, Markhoff & Mittman, P.C. operates as a professional corporation specializing in personal injury and workers’ compensation law. The firm employs a team of attorneys and support staff who manage claims filed through the New York State Workers’ Compensation Board and related administrative bodies. Its practice includes representing individuals injured in workplace accidents, occupational exposure cases, and claims involving repetitive stress injuries.
Workers’ compensation law in New York operates as a no-fault system, designed to provide medical coverage and wage replacement benefits to employees who are injured in the course of their employment. Claims are governed by procedural rules that require timely notice to employers, formal filings with the state board, and ongoing documentation of medical treatment. Disputes may arise regarding the extent of injury, degree of disability, or duration of benefits, often requiring formal hearings before administrative law judges.
The firm’s expanded focus includes additional internal review processes for medical records, employment documentation, and insurance filings. These procedures are intended to ensure that claims submissions align with statutory requirements and evidentiary standards. Attorneys working in this area coordinate with treating physicians, vocational experts, and administrative officials as part of the adjudication process.
In addition to direct representation, Markhoff & Mittman, P.C. closely monitors legislative and regulatory developments that affect workers’ compensation law. Periodic updates to benefit rates, medical treatment guidelines, and administrative rules can alter how claims are evaluated and resolved. The firm incorporates these updates into its internal training and case assessment protocols.
Workers’ compensation cases may intersect with third-party personal injury claims when workplace injuries involve defective equipment, motor vehicle accidents, or unsafe premises controlled by parties other than the employer. In such instances, claims may proceed through separate legal channels, each governed by different standards of proof and recovery. The firm maintains internal separation of these matters to ensure procedural compliance within each forum.
Markhoff & Mittman, P.C. reports that the current expansion does not alter statutory fee structures established under New York workers’ compensation law. Attorney fees in these cases remain subject to approval by the Workers’ Compensation Board, and compensation is contingent upon formal adjudication or settlement. These requirements are intended to preserve regulatory oversight and transparency within the system.
The firm maintains offices serving clients throughout the metropolitan region and manages cases before administrative venues statewide. Its attorneys are admitted to practice in New York and handle filings and hearings required under state law. Additional information about the firm’s legal practice is available through Markhoff & Mittman, P.C.
As workplace injury patterns continue to evolve alongside changes in labor practices and safety standards, workers’ compensation law remains a specialized area requiring administrative precision and familiarity with regulatory frameworks. Markhoff & Mittman, P.C. has indicated that it will continue to evaluate staffing and procedural needs in response to changes in claim volume and regulatory developments. For more information, visit the website to learn more.
###
For more information about Markhoff & Mittman, P.C. – New York City, contact the company here:
Markhoff & Mittman, P.C. – New York City Brian Mittman (212) 897-9004 info@thedisabilityguys.com 1825 Park Ave #901 New York, NY 10035, USA
As winter temperatures fluctuate across Michigan, BC Exteriors has issued guidance on the formation and dangers of ice dams on residential roofs. The company, known for its expertise in roofing services, emphasizes the need for awareness during periods of freeze-thaw cycles that contribute to these common yet damaging occurrences. Homeowners in areas such as Fenton, Linden, and surrounding communities face heightened risks this season, prompting the release of educational information drawn from established industry knowledge.
Ice dams develop when snow accumulates on a roof and begins to melt due to heat escaping from the home below. During warmer daytime hours, this meltwater flows toward the roof’s edges and gutters. However, as temperatures drop at night, the water refreezes, creating thick barriers of ice along the eaves. Over time, repeated cycles build these dams higher, preventing proper drainage. This process is particularly prevalent in regions like Michigan, where freeze-thaw patterns occur frequently throughout the winter months. The article on the BC Exteriors website details how roofs, being warmer than the surrounding air, accelerate this melting and refreezing sequence.
The concerns associated with ice dams extend beyond visible ice buildup. When water backs up behind these dams, it can seep under shingles and into the home’s structure. This intrusion often leads to hidden damage, including saturated insulation, warped wood framing, and compromised ceiling materials. Over prolonged exposure, such issues can result in mold growth, electrical hazards, and weakened roof integrity. If unaddressed, the deterioration may necessitate extensive repairs or even full roof replacement, imposing significant financial burdens on affected households. BC Exteriors notes that early detection is crucial, as the damage frequently remains concealed until spring thaws reveal the extent of the problem.
Chad Beard, owner of BC Exteriors, shared observations from years of handling winter-related roofing issues. “In my experience serving Michigan communities, ice dams often form unnoticed during mild winter spells, only to cause substantial harm when water penetrates the roof layers,” Beard said. “Homeowners frequently report discovering leaks or stains inside their homes after the fact, highlighting how these dams exploit vulnerabilities in older or poorly insulated roofs.”
Prevention plays a key role in mitigating these risks. Homeowners can take proactive steps by clearing accumulated snow from roofs shortly after storms, using appropriate tools to avoid direct contact that might damage shingles. For ongoing protection, the installation of heated cables along roof edges helps maintain channels for meltwater to escape without refreezing. These cables, when properly placed, generate enough warmth to prevent ice accumulation, especially in temperatures above freezing. Professional assessment ensures that such measures are implemented safely, reducing the potential for fire hazards or improper setup. Additionally, regular roof inspections before winter can identify insulation gaps or ventilation issues that exacerbate ice dam formation.
Beyond immediate prevention, addressing underlying factors contributes to long-term roof health. Adequate attic insulation minimizes heat loss, while proper ventilation systems allow warm air to escape without melting rooftop snow unevenly. In cases where ice dams have already formed, safe removal techniques involve applying heat or, in milder conditions, using materials like rock salt to facilitate melting. BC Exteriors advises against amateur attempts at chipping away ice, as this can lead to shingle breakage or personal injury. Instead, engaging qualified professionals ensures thorough evaluation and resolution without compounding the damage.
Beard further elaborated on the broader implications for homeowner safety. “From what we’ve seen in past winters, unaddressed ice dams not only degrade the roof but also pose safety risks through potential structural weakening or ice falls from eaves,” he said. “Prioritizing prevention through professional guidance helps maintain the home’s overall stability and protects residents from unforeseen hazards.”
The recurring nature of ice dams in Michigan stems from the state’s climatic conditions, where rapid temperature shifts are commonplace. Historical weather data indicates that freeze-thaw cycles intensify in late winter, amplifying the likelihood of dam formation. Homeowners in sloped-roof structures are particularly susceptible, as gravity directs meltwater toward the edges. By understanding these dynamics, residents can better prepare their properties, potentially averting costly interventions.
BC Exteriors operates as a veteran-owned company specializing in residential and commercial roofing, gutters, and siding. Established to serve Fenton, Linden, and nearby areas including Bloomfield Hills, Grand Blanc, Brighton, Howell, Rochester, Lake Orion, Clarkston, Flint, Oxford, Shelby Township, Grosse Pointe, Holly, and Lake Fenton, the firm holds certifications as a GAF Master Elite Contractor. This status enables the provision of enhanced warranties, such as the GAF Golden Pledge Limited Warranty, which covers materials and workmanship. The company’s commitment to quality stems from partnerships with leading manufacturers and a focus on precise installations, including drone-assisted inspections for accurate assessments.
###
For more information about BC Exteriors LLC, contact the company here:
BC Exteriors Chad Beard (248) 657-7684 sales@bcexteriors.com 15173 North Rd Ste. 220-10 Fenton, MI 48430
Bangkok, Thailand – December 23, 2025 – PRESSADVANTAGE –
Siam Legal International, a full-service law firm based in Bangkok, is highlighting the critical need for legal support as Thailand intensifies its crackdown on online fraud following the removal of more than 59,000 scam-linked accounts during a coordinated enforcement operation in December.
The operation, conducted between December 8 and 12, involved collaboration between the Royal Thai Police, Meta, and law enforcement agencies from the United States, United Kingdom, Australia, and Singapore. Pol Lt Gen Jirabhop Bhuridej of the Technology Crime Suppression Centre confirmed that authorities are now blocking approximately 4,000 to 5,000 fraudulent advertisements daily in real-time monitoring efforts.
The enforcement action also identified six suspected organizers and recruiters linked to scam networks operating in Poipet, Cambodia, highlighting the cross-border nature of modern cybercrime operations. These developments underscore the growing sophistication of online fraud schemes targeting both Thai nationals and foreign residents.
“The removal of scam accounts represents significant progress, but victims often face ongoing challenges with evidence preservation and asset recovery even after platforms take action,” said Rex Baay, spokesperson for Siam Legal International. “Many foreigners targeted by impersonation pages, fake investment advertisements, and social media fraud require specialized legal coordination with Thai authorities to pursue their cases effectively.”
Siam Legal International’s cybercrime lawyers note that despite increased enforcement efforts, scam activity remains prevalent throughout Thailand’s digital landscape. Common schemes affecting international clients include sophisticated impersonation operations, fraudulent investment platforms, and coordinated social media fraud campaigns that exploit trust and cultural differences.
The firm emphasizes that cybercrime cases frequently involve complex cross-border elements requiring careful legal navigation. Victims may experience financial loss, identity misuse, or reputational damage that persists long after fraudulent pages are removed from social platforms. Early legal consultation becomes essential when individuals or businesses suspect scam exposure or have already suffered financial losses.
The recent enforcement operation demonstrates Thailand’s commitment to combating online fraud through international cooperation and advanced monitoring systems. However, the scale of the problem, with thousands of fraudulent advertisements appearing daily, indicates that comprehensive legal support remains crucial for affected parties.
Siam Legal International maintains offices in Bangkok, Chiang Mai, Phuket, and Hua Hin, providing comprehensive legal services throughout Thailand. The firm’s litigation department, led by attorneys with over two decades of experience, specializes in both civil and criminal matters, including the growing field of cybercrime defense and victim representation. Their bilingual team assists domestic and international clients in navigating Thailand’s judicial system, from initial case assessment through resolution.
###
For more information about Siam Legal International, contact the company here:
Siam Legal International Rex Baay +662 254 8900 info@siam-legal.com 18th Floor, Unit 1806 Two Pacific Place, 142 Sukhumvit Rd, Khlong Toei, Bangkok 10110, Thailand
NEW YORK, NY – December 17, 2025 – PRESSADVANTAGE –
Survivors of Abuse NY announced that attorney Thomas Giuffra is being recognized for his continued work representing survivors of sexual abuse across New York. The acknowledgment follows recent developments in state law expanding civil rights for survivors and reflects the organization’s broader commitment to legal accountability in institutional and professional settings.
“Civil actions in sexual abuse cases require careful handling to ensure survivors understand their rights and the procedures available under state law,” said Thomas Giuffra, attorney at Survivors of Abuse NY. “Our efforts center on providing accurate information and structured legal guidance for individuals pursuing claims through the civil justice system.”
Sexual abuse litigation involves complex legal and emotional dimensions, often extending beyond the immediate facts of misconduct to include questions of institutional responsibility and oversight. Cases may arise from incidents in educational institutions, healthcare facilities, religious organizations, or other environments where authority figures hold positions of trust. These matters typically examine whether organizations implemented sufficient safeguards, reported concerns appropriately, and complied with their obligations under existing laws.
In New York, legislative reforms such as the Child Victims Act and the Adult Survivors Act have reshaped the legal framework governing civil claims related to sexual abuse. These laws extended the time period in which survivors may file lawsuits, allowing many who were previously barred by expired statutes of limitation to seek justice. The provisions have been especially significant in cases involving abuse by individuals in positions of authority, as delayed disclosure is common in trauma-related circumstances.
Legal proceedings in this area often include claims against both individuals and institutions. Courts may evaluate whether organizations fulfilled duties of supervision, adhered to mandatory reporting standards, and enforced adequate policies to prevent abuse. Evidence may involve documentation of internal investigations, employee records, correspondence, and policy manuals. These materials help establish the context in which misconduct occurred and determine whether negligence or systemic failures contributed to the harm.
Survivors of Abuse NY provides information and support regarding civil options available to survivors of abuse. The firm’s attorneys work to clarify the steps involved in initiating claims, the potential remedies under New York law, and the evidentiary standards that govern such cases. Educational initiatives conducted by the organization include informational sessions and outreach programs aimed at helping individuals understand how civil litigation can serve as a pathway toward accountability.
Founded to represent individuals affected by institutional and professional misconduct, Survivors of Abuse NY operates throughout the state with a focus on trauma-informed legal representation. Its attorneys have experience handling matters related to sexual abuse, medical misconduct, and related civil rights issues. The firm’s approach emphasizes procedural transparency, respect for client autonomy, and adherence to ethical and professional standards in all proceedings.
Attorney Thomas Giuffra’s recognition highlights ongoing efforts to improve access to justice for survivors and to enhance institutional accountability across New York. Collaborative work between advocacy organizations, legislators, and legal professionals continues to influence how these cases are handled within both civil and administrative frameworks. By contributing to this dialogue, Survivors of Abuse NY reinforces the importance of transparency, legal education, and ethical responsibility in addressing abuse and preventing future harm.
Survivors of Abuse NY maintains its headquarters in New York and provides services statewide. The firm continues to monitor developments in legislation and case law related to sexual abuse and institutional responsibility. Information about these updates and educational initiatives is regularly made available through the organization’s official platform and community partnerships.
For more information, visit the Survivors of Abuse NY Bronx page. Additional details about New York’s legislative reforms governing sexual abuse claims can be found through official state resources.
###
For more information about Thomas Giuffra, Esq. – The Abuse Lawyer NY, contact the company here:
Thomas Giuffra, Esq. – The Abuse Lawyer NY Thomas Giuffra, Esq. (646) 413-6394 thomas@survivorsofabuseny.com 551 5th Avenue, 29th Floor New York, NY 10017
NEW YORK, NY / ACCESS Newswire / December 23, 2025 / For much of the modern gold trade, trust has been delegated to individual companies. Refiners certified their suppliers. Traders vouched for counterparties. Documentation followed the metal, often across borders and jurisdictions that applied standards unevenly.
That model is breaking down. As global gold markets tighten expectations around responsible sourcing, AML, and ESG compliance, trust is increasingly being evaluated at the jurisdictional level. Markets are no longer asking whether a single participant claims compliance. They are asking whether the environment in which gold is produced, refined, and exported can consistently enforce it.
This shift is redefining how credibility is earned and reshaping where infrastructure must be built.SMX (NASDAQ:SMX) is aligning its precious-metals strategy with that reality.
Putting Extra Shine on Gold
Following its engagement with the Dubai Multi Commodities Centre, the company has moved rapidly into jurisdiction-anchored initiatives, including its newest collaborations with Bougainville Refinery Ltd and digital identity provider FinGo.
The objective is not limited to certifying individual transactions. It is to evaluate how advanced authentication and identity infrastructure can be embedded directly into national-scale supply-chain operations, where enforcement actually matters.
The distinction is critical.
Company-level compliance can be fragmented. Jurisdiction-level infrastructure creates consistency. When verification systems are embedded where sourcing, refining, and export intersect, trust becomes systemic rather than discretionary.
SMX’s role in this transition begins with the material itself. Its molecular-level authentication technology embeds a persistent, invisible identity directly into gold, creating a physical-digital link that survives refining and downstream processing. This ensures that gold remains verifiable regardless of ownership changes or processing stages, a prerequisite for jurisdiction-wide enforcement.
More Than the Sum of Its Parts
TrueGold, a majority-owned subsidiary of SMX, builds on this foundation by positioning verified gold as a distinct, compliant asset class. In a market where regulators and counterparties increasingly differentiate between documented claims and demonstrable proof, this distinction gives jurisdictions a mechanism to offer gold that carries trusted identity by design, not by assertion.
Human identity completes the framework. Jurisdictional trust does not rest solely on material integrity. It depends on accountability across the people who extract, aggregate, refine, and export gold. FinGo’s biometric digital identity infrastructure enables verified attribution of actions and custody changes to real individuals aligned with KYC and AML expectations, including in environments where traditional identity systems are limited or unreliable.
By linking verified humans to verified material at each supply-chain event, the system creates records that withstand scrutiny across borders. This is precisely what jurisdictional credibility requires.
Bougainville Refinery Ltd provides the operational context that elevates the initiative beyond concept. As a licensed refinery and exporter, BRL operates at the point where national policy meets international markets. Embedding SMX and FinGo technologies into real sourcing, refining, and export workflows demonstrates how jurisdictions can operationalize transparency rather than merely legislate it.
A Strategic, Collaborative Effort
The broader implication is strategic. Gold markets are increasingly rewarding environments that can deliver consistency, auditability, and trust at scale. Jurisdictions that can offer verifiable supply chains reduce risk for refiners, financiers, and end markets alike. Those who cannot face growing friction.
SMX’s sequencing reflects an understanding of this shift. Alignment with global market authorities first. Deployment within operational jurisdictions next. Replication as credibility compounds. This is how standards are set in practice, not by decree, but by adoption.
Gold has always been a global asset. Increasingly, it is also a geopolitical one. The future of trusted gold will be shaped not only by companies that comply, but by jurisdictions that can prove it.
By enabling material identity, human accountability, and auditable operations at scale, SMX is positioning itself at the intersection where technology meets sovereignty, and where trust becomes infrastructure.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, forecasts, and assumptions regarding future events involving SMX (NASDAQ: SMX), its technologies, its partnership activities, and its development of molecular marking systems for recycled PET and other materials. Forward looking statements are not historical facts. They involve risks, uncertainties, and factors that may cause actual results to differ materially from those expressed or implied.
Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of SMX’s molecular markers into U.S. recycling markets; the potential for FDA-compliant markers to enable recycled PET to enter food-grade and other regulated applications; the scalability of SMX solutions across diverse global supply chains; anticipated adoption of identity-based verification systems by manufacturers, recyclers, regulators, or brand owners; the potential economic impact of turning recycled plastics into tradeable or monetizable assets; the expected performance of SMX’s Plastic Cycle Token or other digital verification instruments; and the belief that molecular-level authentication may influence pricing, compliance, sustainability reporting, or financial strategies used within the plastics sector.
These forward looking statements are also subject to assumptions regarding regulatory developments; market demand for authenticated recycled content; the pace of corporate adoption of traceability technology; global economic conditions; supply chain constraints; evolving environmental policies; and general industry behavior relating to sustainability commitments and recycling mandates. Risks include, but are not limited to, changes in FDA or international regulatory standards; technological challenges in large-scale deployment of molecular markers; competitive innovations from other companies; operational disruptions in recycling or plastics manufacturing; fluctuations in pricing for virgin or recycled plastics; and the broader economic conditions that influence capital investment and industrial activity.
Detailed risk factors are described in SMX’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.
NEW YORK, NY – December 16, 2025 – PRESSADVANTAGE –
Survivors of Abuse NY announced that attorney Thomas Giuffra is being recognized for his work representing survivors of sexual abuse in Brooklyn, New York. The announcement reflects the organization’s continuing efforts to advance awareness of survivors’ rights and to strengthen accountability within institutions where abuse has occurred. The development coincides with an increase in civil actions filed under state legislation expanding opportunities for survivors to seek justice.
“Civil litigation involving sexual abuse requires a comprehensive understanding of both the law and the trauma that survivors have endured,” said Thomas Giuffra, attorney at Survivors of Abuse NY. “Our objective is to make the civil process more accessible by ensuring individuals understand their rights and the steps involved in pursuing legal action.”
Sexual abuse cases in civil court often involve multiple layers of responsibility, extending beyond individual perpetrators to include institutions that failed to protect victims. These organizations may include schools, medical facilities, religious entities, or youth programs where authority figures hold positions of trust. Claims commonly examine whether appropriate reporting procedures were followed, whether prior warnings were ignored, and whether policies designed to prevent abuse were properly enforced. Such cases also serve an important public function by prompting reforms in oversight and supervision practices.
The legislative framework governing sexual abuse claims in New York has evolved considerably in recent years. The Child Victims Act (CVA) extended the time limits for filing civil claims involving childhood sexual abuse, giving survivors until age fifty-five or within seven years of recognizing the harm to file a lawsuit. The Adult Survivors Act (ASA) created a one-year period for adults who experienced sexual assault to bring claims that had previously been time-barred. Together, these laws have allowed thousands of survivors to seek justice in cases involving individuals and institutions that might otherwise have avoided legal scrutiny.
Litigation under these statutes has brought renewed attention to institutional accountability. Courts have reviewed cases involving allegations against schools, religious organizations, healthcare providers, and other entities with supervisory authority. In many instances, discovery has revealed patterns of misconduct or insufficient internal controls that contributed to systemic failures. Legal proceedings often focus on whether institutions acted with reasonable care, whether employees were properly screened and supervised, and whether prior complaints were addressed in compliance with mandatory reporting requirements. These examinations not only provide redress for survivors but also contribute to ongoing public efforts to prevent future abuse.
Survivors of Abuse NY provides resources that explain the legal process and available remedies under New York law. The firm’s attorneys guide clients through each stage of litigation, from initial investigation and filing to resolution. The organization also conducts educational outreach programs designed to inform the public about legal developments, victims’ rights, and procedural changes that affect survivors. Through these initiatives, Survivors of Abuse NY aims to promote broader understanding of how civil law functions as a mechanism for accountability.
Founded to represent survivors of institutional and professional misconduct, Survivors of Abuse NY applies a trauma-informed approach to legal representation. Its attorneys collaborate with mental health professionals, investigators, and other specialists to ensure that each case is handled with both precision and sensitivity. The firm’s areas of practice include sexual abuse litigation, professional negligence, and institutional liability cases. Its operations throughout New York emphasize transparency, ethical compliance, and respect for survivor autonomy at every stage of the legal process.
Attorney Thomas Giuffra’s recognition highlights ongoing efforts within the state to strengthen the legal structures that protect survivors and to reinforce institutional responsibility. The continued collaboration among legal professionals, advocacy groups, and policymakers is expected to influence future legislation, expand awareness of survivors’ rights, and improve systems for reporting and responding to abuse. These developments illustrate how the civil justice process can serve as a catalyst for reform across educational, medical, and organizational settings.
Survivors of Abuse NY remains active in monitoring changes in case law and legislative updates that affect survivors. The firm continues to share information through its educational initiatives and public resources to ensure that individuals understand their legal options. As reforms continue to shape the landscape of sexual abuse litigation in New York, organizations such as Survivors of Abuse NY play an essential role in supporting transparency and promoting accountability across multiple sectors.
For more information about Thomas Giuffra, Esq. – The Abuse Lawyer NY, contact the company here:
Thomas Giuffra, Esq. – The Abuse Lawyer NY Thomas Giuffra, Esq. (646) 413-6394 thomas@survivorsofabuseny.com 551 5th Avenue, 29th Floor New York, NY 10017
Aglangia, Cyprus – December 16, 2025 – PRESSADVANTAGE –
Trust Insurance, one of Cyprus’ most established and trusted insurance providers, has announced the expansion of its health insurance services across the island, aiming to make private healthcare coverage more accessible to individuals and families. This initiative comes as the company seeks to complement the existing GESY public healthcare system, highlighting the value of maintaining private health insurance for comprehensive protection and faster access to medical services.
Since the introduction of the General Healthcare System (GESY), Cyprus has made major strides toward universal healthcare coverage for residents. However, many citizens continue to recognise the benefits of having an additional layer of protection through private health insurance. Trust Insurance is working to ensure that individuals throughout Cyprus understand how private plans can enhance their healthcare experience, particularly when it comes to specialist consultations, hospital admissions, and international medical coverage.
The company’s expanded health insurance offerings are designed to provide flexibility, efficiency, and choice. Policyholders can access a wider network of private hospitals, clinics, and specialists, allowing them to receive timely care without extended waiting periods. With a range of policy options, Trust Insurance enables customers to tailor coverage according to their medical needs, lifestyle, and budget.
A spokesperson for Trust Insurance stated, “Cyprus has made significant progress with the GESY system, providing essential healthcare access for everyone. However, there are still situations where private health insurance can make a meaningful difference, whether that’s faster treatment times, access to private facilities, or broader international coverage. Our goal is to make sure people in Cyprus have both the security of GESY and the confidence of knowing they are fully protected when they need medical attention.”
The spokesperson added that the expansion is driven by increased demand for personalised healthcare coverage, as many residents are seeking additional protection beyond what GESY offers. Private health insurance allows individuals to receive treatment from their preferred doctors, access premium hospital accommodations, and receive coverage for treatments abroad if necessary.
Trust Insurance’s health insurance plans are available to residents across Cyprus, including those in Nicosia, Limassol, Larnaca, Paphos, and Famagusta. By broadening its service availability, the company aims to support both local families and expatriates living on the island. The initiative underscores Trust Insurance’s long-standing commitment to improving the quality and accessibility of healthcare coverage for everyone in the country.
Private health insurance can play an essential role in providing a safety net for unexpected medical events or emergencies. While GESY covers many general treatments and services, it does not always include certain specialist procedures, advanced diagnostic tests, or private hospital stays. With Trust Insurance’s health coverage, individuals gain access to a wider spectrum of healthcare options, ensuring both comfort and control over their medical choices.
As the healthcare landscape continues to evolve, Trust Insurance remains focused on helping citizens make informed decisions about their medical coverage. The company has invested heavily in digital tools and customer support channels, allowing clients to manage their health policies online, submit claims efficiently, and receive guidance from trained representatives.
The spokesperson noted, “Our health is one of the most important investments we can make. While GESY provides an important foundation for public healthcare in Cyprus, combining it with private insurance gives people the best of both worlds: security, flexibility, and peace of mind. We want to empower individuals to make choices that truly serve their needs, without compromising on quality of care.”
Through its enhanced presence across Cyprus, Trust Insurance continues to strengthen its reputation as a provider of dependable and transparent insurance solutions. The company’s health insurance services reflect its ongoing mission to protect what matters most, people’s well-being.
Trust Insurance’s comprehensive approach ensures that policyholders have continuous access to quality care, whether through Cyprus’ growing network of private healthcare providers or through international coverage when travelling abroad. By expanding its health insurance portfolio, Trust Insurance reaffirms its role as a key player in supporting the island’s evolving healthcare ecosystem.
For more information on health insurance options in Cyprus, residents are encouraged to visit the Trust Insurance website or contact the company directly for assistance in selecting a suitable plan.
About Trust Insurance: Trust Insurance is a leading insurance provider in Cyprus, offering a wide range of services, including car, health, home, and business insurance. With a strong presence across the island, the company is dedicated to delivering reliable coverage, innovative solutions, and outstanding customer service. Trust Insurance continues to uphold its reputation for dependability and transparency within the Cypriot market.
###
For more information about Trust Insurance – Nicosia, contact the company here:
LOS ANGELES, CA / ACCESS Newswire / December 23, 2025 / EVCS, the largest, privately held electric vehicle fast-charging network on the West Coast, today announced the appointment of Eric Danner as Chief Executive Officer, effective January 1, 2026. Danner succeeds Founder Gustavo Occhiuzzo, who will transition into the role of Executive Chairman & Chief Strategy Officer, where he will continue to guide the company’s long-term vision and strategic growth initiatives.
Eric Danner is a seasoned operations and finance executive leader with deep experience in the telecommunications and broadband sector, having held leadership roles at companies including ElektraFi and Zayo Group. He brings a proven track record of scaling organizations, driving operational excellence, and leading through periods of rapid industry transformation.
“EVCS is at an important inflection point as we continue to expand our network and serve more drivers across the West Coast,” said Gustavo Occhiuzzo, Founder, Executive Chairman & Chief Strategy Officer of EVCS. “Eric is a proven leader with the operational and financial discipline needed to scale complex infrastructure platforms. I’m excited to partner closely with him as he leads the company into its next phase of growth.”
Eric Danner shared: “I am honored to join EVCS and look forward to working closely with Gustavo and the team to build on the company’s strong foundation. Together, we will continue to expand access to clean, affordable, and convenient EV charging solutions, supporting the transition to carbon-free transportation.”
About EVCS EVCS was founded in 2018 and has quickly become the largest privately held, electric vehicle fast charging network on the West Coast, home to 50% of the EVs in the U.S. EVCS is committed to leading the electric transportation revolution by rapidly expanding access to fast, affordable, reliable, and conveniently located public EV charging. Powered by 100% renewable energy, EVCS is disrupting the mobility industry through a turn-key approach that utilizes public and private funding sources to accelerate the installation of fast charging stations. EVCS has secured private and public funding to install, own, and operate over 1,600 chargers across over 350 public and private site hosts, including Fortune 500 companies and underrepresented communities. In addition, EVCS offers flexible subscription charging plans to fit a variety of driving needs. These include options tailored for gig and high-mileage drivers, providing significant potential savings. For more information, visit www.evcs.com.
Media Contact: Justin Arita Senior Growth Manager, EVCS justina@evcs.com
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®
Recent financings create runway for prospective new 2026 development opportunities
KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ” or the “ Lexaria Study “), recently completed in Australia, focusing on 4 DehydraTECH ® ( “DHT” ) study arms relative to the Rybelsus® control study arm.
“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much as approximately half as compared to the world’s only approved oral-based GLP-1 medication, Rybelsus ® . The receipt of the results allows us to now relay the dataset to our Material Transfer Agreement partner.”
“The final study results follow our recent financing activities,” Mr. Christopher continued. “We are thrilled to have opportunistically raised a gross total of $7.5 million over two transactions, each at share price high points at the time, since our fiscal year-ended on August 31, 2025. As previously reported, we had limited resources remaining ($1.8 million in cash on hand as of August 31, 2025) which hindered our ability and runway to proceed forward with our DehydraTECH research and partnering efforts. The financings allow us to fund prospective new development opportunities for the entirety of calendar 2026, the details of which are in the process of being finalized and will be forthcoming in due course.”
Adverse Events
After the full 12 weeks of treatment, followed by a 4-week follow-up period (16-week study duration overall), all 4 DHT test articles appeared to be safe and well tolerated thus meeting the primary endpoint objective of the Study. Each of the DHT arms had lower rates of overall treatment emergent adverse events (“ AEs “) and gastrointestinal (“ GI “) AEs compared to the Rybelsus ® control arm:
GLP-1-H24
EOS Results
DHT-CBD
250 mg BID x 12 weeks
(Arm 1; n=27)
DHT-semaglutide
3.5 mg QD x 4 weeks followed by 7 mg QD x 8 weeks
(Arm 2; n=24)
DHT-CBD 250 mg BID with DHT-semaglutide 3.5 mg QD x 12 weeks
(Arm 3; n=25)
Rybelsus ®
3 mg QD x 4 weeks followed by 7 mg QD x 8 weeks
(Arm 4; n = 25) (Study Control Arm)
DHT-tirzepatide
20 mg QD x 4 weeks followed by 40 mg x 8 weeks
(Arm 5; n=25)
Persons with at least 1 AE
88.9%
83.3%
92.0%
100%
76.0%
Total AEs
105
73
86
140
128
Total AEs as a % of Control
75.0%
52.1%
61.4%
N/A
91.4%
Total GI AEs
21
32
31
71
28
GI AEs as a % of Control
29.6%
45.1%
43.7%
N/A
39.4%
Nausea
6
10
3
21
3
Vomiting
0
2
2
6
0
Diarrhea
7
6
10
15
12
All other GI AEs
8
14
16
29
13
n = number of patients included in each study group for safety and tolerability assessments
Abbreviations: EOS: End of Study (week 16); BID: twice daily; CBD: cannabidiol; QD: once daily.
Of the DHT formulations evaluated, DehydraTECH-semaglutide (“ DHT-semaglutide “) was the top performer in total AE reductions. There was a 47.9% reduction in the total quantity of AEs derived from DHT-semaglutide vs. Rybelsus ® . There was also a statistically significant (nominal p-value <0.05) 54.9% reduction in GI AEs from DHT-semaglutide vs. Rybelsus®. It should be noted that the DHT-semaglutide AE percent reductions were higher at the end of the Study than they were at the 8-week interim analysis mark previously reported upon .
It is also noteworthy that there were marked reductions in GI AEs for all 4 DHT treatment arms relative to Rybelsus ® , most notably in the instances of nausea, vomiting and diarrhea.
HbA1c and Bodyweight
Assessments of the magnitude of decreases in glycated haemoglobin (“ HbA1c “), as a primary blood test for blood sugar levels, and body weight were the major secondary efficacy endpoints of the Study. The findings for each variable at both the week 12 and week 16 points were as follows:
GLP-1-H24
12-week and EOS
Results
DHT-CBD
250 mg BID x 12 weeks
(Arm 1; n=27)
DHT-semaglutide
3.5 mg QD x 4 weeks followed by 7 mg QD x 8 weeks
(Arm 2; n=24)
DHT-CBD 250 mg BID with DHT-semaglutide 3.5 mg QD x 12 weeks
(Arm 3; n=25)
Rybelsus ®
3 mg QD x 4 weeks followed by 7 mg QD x 8 weeks
(Arm 4; n = 25) (Study Control Arm)
DHT-tirzepatide
20 mg QD x 4 weeks followed by 40 mg x 8 weeks
(Arm 5; n=25)
HbA1c
Wk 12
-0.08%
(range -0.4 to +0.3%)
Wk 12
-0.12%
(range -0.9 to +0.3%)
Wk 12
-0.05% b
(range -0.5 to +0.3%)
Wk 12
-0.24%
(range -0.6 to +0.4%)
Wk 12
+0.07% b
(range -0.7 to +0.6%)
EOS Wk 16
+0.01% b
(range -0.3 to +0.2%)
EOS Wk 16
-0.08%
(range -0.5 to +0.3%)
EOS Wk 16
+0.03% b
(range -0.3 to +0.4%)
EOS Wk 16
-0.14%
(range -0.4 to +0.3%)
EOS Wk 16
+0.12% b
(range -0.8 to +0.5%)
Bodyweight
Wk 12
+0.06 Kg or
-0.13% b
(range -4.3 to +5.9 Kg)
Wk 12
-0.87 Kg or
-0.94% b
(range -7.4 to +5.0 Kg)
Wk 12
-0.90 Kg or
-0.93% b
(range -6.8 to +4.2 Kg)
Wk 12
-5.29 Kg or
-5.45%
(range -12.4 to -0.1 Kg)
Wk 12
+0.67 Kg or +0.69% b
(range -10.1 to +10.3 Kg)
EOS Wk 16
+0.77 Kg or +0.68% b
(range -7.7 to +4.2 Kg)
EOS Wk 16
-1.20 Kg or
-1.31% b
(range -8.7 to +6.1 Kg)
EOS Wk 16
-0.59 Kg or
-0.65% b
(range -7.4 to +5.3 Kg)
EOS Wk 16
-4.95 Kg or
-5.14%
(range -11.8 to +2.5 Kg)
EOS Wk 16
+0.77 Kg or +0.82% b
(range -11.6 to +8.8 Kg)
n = number of patients included in each study group for HbA1c and body weight efficacy assessments
Abbreviations: EOS: End of Study (week 16); Wk: week; BID: twice daily; CBD: cannabidiol; QD: once daily.
b Instances where nominal p-values were < 0.05 for least-square mean changes relative to Rybelsus ® control arm upon mixed model for repeated measures (MMRM) analysis
The bodyweight reduction performance, on the other hand, was improved for the Rybelsus ® control arm versus all DHT arms at both the week 12 and week 16 evaluations, as was also witnessed at the 8-week interim analysis timepoint previously reported. Of note, a comparison to published Rybelsus ® bodyweight reduction performance levels in Novo Nordisk’s ® Pioneer 1 phase 3a randomized study conducted in 703 patients with type 2 diabetes, with similar daily doses of Rybelsus ® semaglutide administered after 26 weeks of dosing, revealed much lower bodyweight reduction performance which was comparable to that achieved with DHT-semaglutide in the current Study:
Pioneer 1: 26-Week Final Results
3 mg Rybelsus®
7 mg
Rybelsus®
14 mg
Rybelsus®
Body Weight
Baseline = 88.1kg
-1.32 kg or
-1.5%
-2.02 kg or
-2.3%
-3.26 kg or
-3.7%
The reasons for the apparent anomaly of exceptionally high Rybelsus ® bodyweight performance levels in the current Study are presently unknown, but likely related to the differing patient population and/or small sample size of the Lexaria Study, where it is notable that the range as tabulated above in bodyweight reductions was wide for all arms in the Lexaria Study. The historical studies conducted in thousands of persons are more likely to be representative of real-world performance.
Overall Conclusions and Next Steps
Study GLP-1-H24-4 met its primary endpoint objectives showing good safety and tolerability of all DHT test articles with clear reductions in total and GI-specific AEs relative to the Rybelsus ® control arm. The Study demonstrated positive findings across numerous parameters with comparability, and in some instances, superiority to the Rybelsus ® control arm.
Based on the findings from this Study, Lexaria considers the DHT-semaglutide test article to be most worthy of continued investigation for the therapeutic indication studied. However, it would seem most prudent for any such work to include the salcaprozate sodium ( “SNAC” ) ingredient chemistry present in Lexaria’s DHT-semaglutide formulations originally tested in its previous human clinical studies GLP-1-H24-1 and GLP-1-H24-2 , (Human Pilot Studies #1 and #2), but not included in the current Study. These previous human clinical studies evidenced the strongest DHT-semaglutide efficacy performance superior to the Rybelsus ® control used therein, while also maintaining improvements in safety and tolerability relatively speaking with the DHT-semaglutide formulation studied.
Moving forward, Lexaria intends to consider its options to perform prospective follow on human clinical testing with a DehydraTECH + SNAC + semaglutide composition compared to Rybelsus ® accordingly, to expand and build upon the learnings in aggregate from studies GLP-1-H24-1, GLP-1-H24-2 and GLP-1-H24-4. Details will be provided on this if/when Lexaria formalizes plans to perform such a study.
In parallel, now that public release of final results from study GLP-1-H24-4 has occurred, Lexaria will proceed with relaying the dataset to the pharmaceutical company ( “PharmaCo” ) that Lexaria has a Material Transfer Agreement ( “MTA” ) in place with. As previously announced , this MTA was recently extended through April 30, 2026 to accommodate the time needed for PharmaCo’s receipt and review of this dataset, after which time further information will be provided.
Lexaria remains hopeful that achievement of its primary endpoint in the current Study, with DehydraTECH evidencing superior safety and tolerability and a significant reduction in GI side effects especially relative to Rybelsus ® , will be considered attractive and compelling to PharmaCo in its deliberations about potential next steps in its relationship with Lexaria. This would be consistent with the pharmaceutical industry’s strong appetite in the related therapeutic sectors for improvements in unwanted side effects as Lexaria previously reported .
As noted above, Lexaria was pleased to have recently raised additional capital through financings intended to allow it to fund prospective new development opportunities through the entirety of calendar 2026; the details of which are in the process of being finalized and will be forthcoming in due course. Deployment of these funds may include, but not be limited to, progressing its prospective further human clinical testing upon DehydraTECH + SNAC + semaglutide as noted above, as well as, supporting other complementary research and development program work in the Glucagon-Like Peptide-1 ( “GLP-1” ) sector.
About the Study
Study GLP-1-H24-4 investigated 126 overweight, obese, pre-diabetic and/or type-2 diabetic human volunteers/patients. The primary endpoint in this study was to assess impacts upon safety and tolerability based on the incidence of treatment emergent adverse events. This Study initially included three DehydraTECH arms testing DehydraTECH-CBD, DehydraTECH-semaglutide and a combination of DehydraTECH-CBD with DehydraTECH-semaglutide. Performance across these three initial study arms was monitored compared to commercially available Rybelsus ® as the Study positive control group. Of note, the DehydraTECH-semaglutide composition evaluated used pure semaglutide processed without inclusion of the SNAC ingredient found in the Rybelsus ® composition differing, therefore, from the DehydraTECH-semaglutide composition previously tested by Lexaria in its studies GLP-1-H24-1 and GLP-1-H24-2 that used reformulated commercially available SNAC-inclusive Rybelsus ® as the semaglutide active substance input. In addition, this Study was expanded after initiation to incorporate an orally delivered DehydraTECH-tirzepatide arm to assess safety, tolerability and effectiveness in an effort to potentially advance the findings discovered with Lexaria’s previous DehydraTECH-tirzepatide human pilot study GLP-1-H24-3. Of note, however, the DehydraTECH-tirzepatide composition evaluated in study GLP-1-H24-4 used pure tirzepatide as the active substance input instead of reformulated commercially available Zepbound ® differing, therefore, compared to the composition utilized in study GLP-1-H24-3.
In an attempt to accommodate the large amount of data captured in study GLP-1-H24-4, additional non-primary (secondary/exploratory) endpoint results are expected to be released next week.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic – Head of Investor Relations ir@lexariabioscience.com Phone: 250-765-6424, ext 202
